logo dark logo light logo
  • 首页
  • 关于我们
    • 背景
    • 投资战略
    • 团队
  • 投资组合
  • 新闻中心
  • 联系我们
  • English
  • 投资者登录
mobile-logo
  • 首页
  • 关于我们
    • 背景
    • 投资战略
    • 团队
  • 投资组合
  • 新闻中心
  • 联系我们
  • English
  • 投资者登录
 

新闻中心

30 7月 2020
by admin
in Uncategorized
Comments
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Result
28 7月 2020
by admin
in Uncategorized
Comments
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
13 7月 2020
by admin
in Uncategorized
Comments
Quan Capital leads Citrine Medicine’ s Series A round
22 6月 2020
by admin
in Uncategorized
Comments
TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH THE COMBINATION OF TPST-1120 PLUS NIVOLUMAB IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
28 5月 2020
by admin
in Uncategorized
Comments
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
07 5月 2020
by admin
in Uncategorized
Comments
TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TPST-1495 CLINICAL STUDY: DUAL EP2/4 ANTAGONIST TARGETING SOLID TUMORS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24

中国上海市浦东新区张江高科技园区金科路4560号金创大厦3号楼8楼,201210
电话: +86 21 6163 2598  |  传真: +86 21 6163 2570  |  邮件: info@quancapital.com

© Quan Capital. All rights reserved. Credit: Website Design